ApoB, Lp(a) and Advanced Lipid Testing

What this page covers

Beyond the standard cholesterol panel, two blood tests appear often in "longevity" and heart-health discussions: apolipoprotein B (ApoB) and lipoprotein(a), written Lp(a). This page explains what they are, what current guidelines and consensus statements say, and where the evidence stops. It does not interpret anyone's result and does not suggest treatments. Evidence labels: established, promising but limited, mixed, insufficient evidence. Education only.

Plain definitions

LDL cholesterol (LDL-C) measures the cholesterol carried inside certain particles. ApoB is a protein found on these particles, so it tracks the number of particles rather than the amount of cholesterol they hold. Reviewers describe cardiovascular risk as more closely related to the number of atherogenic (artery-clogging) particles than to the total mass of cholesterol within them. [1] Lp(a) is a modified LDL-like particle that also contains a protein called apolipoprotein(a), and its levels are highly heritable and variable between people. [2] Standard tests are covered in Standard blood tests and healthy aging.

ApoB

What the research shows. A review of "discordance" studies, which compare measures in people whose results disagree, concluded that ApoB and LDL particle numbers were more accurate indices of cardiovascular risk than LDL-C or non-HDL-C. [1] Not every analysis agrees that ApoB is clearly better. In a 2023 cohort of 9,191 statin-treated people with coronary artery disease, high ApoB with low LDL-C and high non-HDL-C with low LDL-C each carried higher risk of heart attack, but no difference was seen between ApoB and non-HDL-C. [3] A pooled analysis of prospective studies found similar hazard ratios for heart disease with the ApoB/ApoA-I ratio (1.49) and the non-HDL/HDL cholesterol ratio (1.50), and concluded that fasting was not needed. [4]

Guideline position. Per a summary of the 2026 ACC/AHA guideline, ApoB may be used to assess residual risk and guide treatment in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides or known cardiovascular disease who have already reached their LDL-C and non-HDL-C goals. The guideline notes ApoB may be a more accurate risk marker than LDL-C in those groups. [5] That is a targeted use, not a recommendation to test all healthy people.

Label: established as a risk marker in clinical guidelines for specific groups; insufficient evidence that routine ApoB testing in healthy people lengthens life.

Lipoprotein(a)

What it is. Lp(a) levels are largely set by genes and remain relatively stable over a lifetime, so lifestyle changes affect them little. [5]

What the consensus says. A 2022 European Atherosclerosis Society statement concluded that epidemiologic and genetic studies of hundreds of thousands of people support a causal, continuous link between Lp(a) concentration and cardiovascular outcomes, and that elevated Lp(a) is a risk factor even at very low LDL-C. It recommended measuring Lp(a) at least once in adults. [6] It also stated that current findings do not support Lp(a) as a risk factor for venous blood clots. [6] The 2026 ACC/AHA guideline, as summarized in trade and society sources, likewise recommends measuring Lp(a) at least once in adulthood and describes 125 nmol/L (50 mg/dL) or higher as high, with repeat testing generally not needed. [5] An earlier UK statement listed narrower reasons to measure, such as personal or family history of early heart disease. [2] Guidance differs by organization, so ask your clinician which applies to you.

Treatment status. The European statement describes lipoprotein apheresis, a procedure that filters blood, as an option for very high Lp(a) with progressive cardiovascular disease. [6] A 2026 trial report calls apheresis the only approved treatment for elevated Lp(a). [7] Drugs aimed at lowering Lp(a) are still being studied. A 2026 commentary reports that the first large outcomes trial of pelacarsen, announced in September 2026 as topline results, lowered Lp(a) but did not reduce the primary composite cardiovascular endpoint in people with established cardiovascular disease; full data were still awaited. [8] Separately, a 51-person trial in people already receiving apheresis tested whether pelacarsen reduced apheresis sessions. [7] A lower Lp(a) number on a lab report is therefore not the same as proven benefit.

Label: testing guidance established in major consensus statements; Lp(a)-lowering drugs: insufficient evidence of clinical benefit, with an outcomes trial reported as neutral and full results awaited.

Related reading

Biomarkers and Biological Age Tests, hs-CRP and inflammation markers and Interpreting Test Results Without Overinterpreting.